Meta Information
ID:myostatin-inhibitors
Name:Myostatin Inhibitors
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-07-02T07:03:07Z
Model
phase-b-newfiles-claude-opus-4.8
Interactions
Target id:
/intervention/resistance-training
Target name:
Resistance training
Severity:
moderate
Interaction type:
synergistic
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Myostatin inhibition and resistance training both promote muscle growth and may be complementary.
Actionable advice:
Reasonable to combine for muscle goals; no specific harm, monitor for tendon/joint strain from rapid gains.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Myostatin inhibition removes a brake on muscle hypertrophy; complementary with resistance training. Mechanistic.
Label source:
Class inference
Action type:
informational_none
Target id:
/condition/fda-compounding-risk
Target name:
Regulatory / experimental status
Severity:
major
Interaction type:
adverse
Nature:
informational
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Most myostatin inhibitors (e.g., follistatin, ACE-031-type agents) are experimental with limited human safety data.
Actionable advice:
Most are unapproved/experimental; approved uses are narrow. Verify regulatory status and source quality.
Validation status:
validated_via_regulatory
Evidence tier:
tier_b
Evidence basis:
regulatory_advisory_verbatim
Evidence anchors:
Exact phrase from label:
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
Label source:
US FDA compounding advisory. Most myostatin inhibitors are unapproved/experimental.
Action type:
informational_none
Target id:
/class/corticosteroids
Target name:
Corticosteroids
Severity:
minor
Interaction type:
diminishing
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Corticosteroids promote muscle breakdown, which opposes the muscle-building goal of myostatin inhibition.
Actionable advice:
Chronic steroids will blunt muscle gains; a mechanistic opposition, not a safety hazard.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Glucocorticoid-driven muscle catabolism opposes myostatin-inhibition anabolism. Mechanistic.
Label source:
Class inference
Action type:
informational_none